MNPR Monopar Therapeutics Inc. Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MNPR
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 22
- List Date
- 2019-12-19
- CIK
- 0001645469
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.86)
- Headquarters
- Wilmette, IL
- Homepage
- https://www.monopartx.com
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensin…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 32.86% | -13.24% | 54.31% | -9.32% | 97.75% | -8.53% | 25.64% |
| Feb | -8.18% | 5.46% | -0.95% | 123.90% | -19.38% | -16.30% | 14.09% |
| Mar | -13.41% | -21.05% | -50.18% | -23.99% | 17.72% | 2.47% | -14.74% |
| Apr | -3.38% | -12.64% | -21.32% | -2.78% | 25.10% | -5.85% | -3.48% |
| May | -1.55% | -6.55% | -5.96% | -5.98% | -26.47% | 22.14% | -4.06% |
| Jun | 2.26% | 10.22% | -18.57% | -5.17% | 19.23% | 43.77% | 8.62% |
| Jul | -9.23% | -16.60% | -9.96% | -5.60% | 22.71% | 13.63% | -0.84% |
| Aug | -2.82% | -11.39% | -10.90% | -31.04% | -16.07% | 0.26% | -11.99% |
| Sep | -5.98% | -15.08% | -2.68% | 184.39% | 140.70% | -32.24% | 44.85% |
| Oct | 4.35% | 54.72% | -28.21% | 186.81% | 1.69% | -9.81% | 34.93% |
| Nov | -7.53% | -3.88% | -47.25% | 54.00% | 2.60% | 0.00%* | -0.34% |
| Dec | -26.71% | -10.23% | 3.09% | -0.05% | -21.38% | -- | -11.06% |
| Total | -39.73% | -45.54% | -86.02% | 993.30% | 318.55% | -9.70% | 188.48% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $73.77
SMA 50: $90.26
SMA 200: $77.23
Current: $66.59
EMA 12: $71.81
EMA 26: $77.14
MACD: -5.3342 | Signal: 0.6691
BEARISH
ADX (14): 39.36
TREND
+DI: 13.48
−DI: 30.01
Momentum Oscillators
RSI (14): 29.00
OVERSOLD
Stoch %K: 21.10
Stoch %D: 24.21
Williams %R: -84.18
Volume & Volatility
BB Upper: $82.75
BB Lower: $64.79
NEUTRAL
OBV: -1,547,775
Vol SMA 20: 147,759
Vol ROC: 128.40%
ATR: $4.12
True Range: $5.37
HV 20: 52.5%
HV 30: 49.8%
HV 60: 50.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-01T00:00:00 – 2026-10-30T00:00:00
AI Analysis
LLM Stock Analysis Report: MNPR
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers and Primary Risks:
- Recent positive news headlines driving price appreciation
- Strong technical momentum signals, including a bullish MACD crossover
- High volatility, indicating potential for increased risk
- No earnings data available to inform investment thesis
Investment Thesis: MNPR has shown significant price appreciation in recent weeks, driven by a series of positive news headlines. The stock's high beta and strong momentum indicators suggest continued upside potential, but also highlight the risks associated with this volatility.
Recent News Sentiment Impact: Positive news sentiment (4/5) has contributed to MNPR's upward price movement.
Technical Analysis
Trend Direction: Short-term: Uptrend (SMA 20 above current price) Medium-term: Uptrend (SMA 50 above SMA 200) Long-term: Uptrend (SMA 200 above historical lows)
Support/Resistance Levels:
- Upper Bollinger Band ($122.91) - potential resistance
- Middle Band ($114.88) - key support level
Momentum Signals: RSI: Neutral (51.00) MACD: Bullish (crossover above signal line) Bollinger Bands: Neutral (price within range)
Volume Analysis: Volume SMA 20 indicates increasing buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines, including Phase 2 ALXN1840 data and business updates, have driven recent price appreciation.
Sentiment Assessment: Positive sentiment dominates, with a sentiment score of 4/5.
Catalyst Identification: Upcoming events or earnings announcements are not currently scheduled.
Market Narrative: Recent news headlines support the uptrend in MNPR's stock price.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock (beta >1.50) with potential for increased volatility.
Volatility Regime: Current high-volatility regime may persist, driven by market and company-specific factors.
Options Market Signals: No options data available.
Downside Protection: Support levels at SMA 20 ($114.88) and middle Bollinger Band ($114.88).
Market Context & Positioning
Sector Performance: MNPR's sector has been relatively strong, with a correlation of 0.26 to the broader market.
Institutional Activity: Volume patterns suggest institutional interest in the stock.
Correlation Analysis: R-squared interpretation indicates moderate correlation (0.75) between MNPR and the market.
Relative Valuation: Position within trading range, with potential for further upside or pullback.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band ($122.91) - potential resistance
- Middle Band ($114.88) - key support level
Breakout/Breakdown Levels: SMA 20 ($114.88) - potential breakout/breakdown zone.
Time-Sensitive Catalysts: No upcoming events or earnings announcements scheduled.
Risk Management: Stop-loss levels at SMA 50 ($105.83) and lower Bollinger Band ($106.85).
Generated
News
All MNPR news →
MNPR Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.2407
Alpha: -20.14%
Correlation: 0.2530
R-Squared: 6.4%
Stock Volatility: 62.7%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MNPR
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $4.7M | #2093 of 3716 | -5.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $3.4M | #2399 of 6285 | -36.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MNPR Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
MNPR Insider Trading (Form 4)
Latest: 2026-10-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Chandler Robinson | Chief Executive Officer | Tax (F) | −597 | $92.59 | -$55.3K | EDGAR |
| 2026-10-05 | Christopher M Starr | Director | Mixed | — | $39.25 | -$659.3K | EDGAR |
| 2026-10-02 | Andrew Cittadine | Chief Operating Officer | Mixed | +2,440 | $79.67 | -$154.9K | EDGAR |
| 2026-10-02 | Quan Anh Vu | Chief Financial Officer | Mixed | +434 | $79.67 | -$14.3K | EDGAR |
| 2026-10-02 | Chandler Robinson | Chief Executive Officer | Mixed | +5,457 | $79.67 | -$346.1K | EDGAR |
| 2026-09-28 | Chandler Robinson | Chief Executive Officer | Mixed | — | $54.87 | -$1.93M | EDGAR |
| 2026-08-28 | Raymond Anderson | Director | Mixed | — | $70.99 | -$257.6K | EDGAR |
| 2026-08-28 | Kim R Tsuchimoto | Director | Mixed | — | $66.71 | -$365.4K | EDGAR |
| 2026-08-27 | Raymond Anderson | Director | Sell (S) | −3,142 | $111.77 | -$351.2K | EDGAR |
| 2026-08-27 | Patrice Rioux | Mixed | +1,379 | $0.09 | -$104 | EDGAR | |
| 2026-08-27 | Kim R Tsuchimoto | Director | Sell (S) | −4,090 | $111.39 | -$455.6K | EDGAR |
| 2026-07-02 | Quan Anh Vu | Chief Financial Officer | Mixed | +721 | $92.59 | -$46.9K | EDGAR |
| 2026-07-02 | Andrew Cittadine | Chief Operating Officer | Mixed | +2,945 | $92.59 | -$213.8K | EDGAR |
| 2026-07-02 | Chandler Robinson | Chief Executive Officer | Mixed | +8,789 | $92.59 | -$378.1K | EDGAR |
| 2026-04-02 | Andrew Cittadine | Chief Operating Officer | Mixed | +1,943 | $54.79 | -$86.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MNPR Insider Holdings
11 insiders · @ $66.59
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas V. O'Halloran | 822,255 | $54.75M | -$5.83M | 1 | 2025-04-04 | |
| 2 | Arthur J Klausner | Director | 620,302 | $41.31M | -$343.9K | 23 | 2025-12-19 |
| 3 | Andrew Paul Mazar | Chief Scientific Officer | 305,359 | $20.33M | -$179.15M | 12 | 2025-09-26 |
| 4 | Chandler Robinson | Chief Executive Officer | 166,942 | $11.12M | -$3.23M | 35 | 2026-10-20 |
| 5 | Diane Hendricks | 10%+ Owner | 93,750 | $6.24M | $3.75M | 2 | 2025-12-17 |
| 6 | Andrew Cittadine | Chief Operating Officer | 58,054 | $3.87M | $149.7K | 30 | 2026-10-02 |
| 7 | Christopher M Starr | Director | 15,852 | $1.06M | -$1.33M | 23 | 2026-10-05 |
| 8 | Kim R Tsuchimoto | Director | 14,476 | $964.0K | -$1.26M | 25 | 2026-08-28 |
| 9 | Raymond Anderson | Director | 6,775 | $451.1K | -$703.0K | 23 | 2026-08-28 |
| 10 | Patrice Rioux | 5,065 | $337.3K | -$111 | 9 | 2026-08-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MNPR Board & Officers
As of SEC filings through Oct 20, 2026Directors 7
- Arthur J Klausner · since Jan 8, 2018
- Christopher M Starr · since Jan 8, 2018
- Raymond Anderson · since Jan 8, 2018
- Kim R Tsuchimoto · listed since Apr 2023
- Lavina Talukdar · since Feb 21, 2025
- Nicole Sweeny · since Jun 22, 2026
- Chandler Robinson · listed since Jul 2026
Officers 4
- Chandler Robinson · Chief Executive Officer · listed since Jul 2026
- Quan Anh Vu · Chief Financial Officer · since Mar 3, 2025
- Andrew Cittadine · Chief Operating Officer · since Jun 1, 2021
- Susan Rodriguez · Ccso · since Mar 2, 2026
Changes in the last 10 years (48)
| Jul 2, 2026 | Chandler Robinson first listed as a director in an SEC filing |
| Jul 2, 2026 | Chandler Robinson first listed as Chief Executive Officer in an SEC filing |
| Jun 22, 2026 | Nicole Sweeny became a director |
| Mar 2, 2026 | Susan Rodriguez became Ccso |
| Dec 17, 2025 | Diane Hendricks reported in an SEC filing no longer being a 10% owner |
| Sep 26, 2025 | Thomas V. O'Halloran reported in an SEC filing no longer being a 10% owner |
| Sep 26, 2025 | Tactic Pharma LLC reported in an SEC filing no longer being a director |
| Sep 26, 2025 | Tactic Pharma LLC reported in an SEC filing no longer being a 10% owner |
| Sep 26, 2025 | Tactic Pharma LLC reported in an SEC filing no longer being Chief Executive Officer |
| Sep 26, 2025 | Michael J Brown reported in an SEC filing no longer being a director |
| Sep 26, 2025 | Chandler Robinson reported in an SEC filing no longer being a director |
| Sep 26, 2025 | Chandler Robinson reported in an SEC filing no longer being Chief Executive Officer |
| Sep 26, 2025 | Andrew Paul Mazar reported in an SEC filing no longer being a director |
| Sep 26, 2025 | Andrew Paul Mazar reported in an SEC filing no longer being Chief Scientific Officer |
| Apr 4, 2025 | Tactic Pharma LLC first listed as a director in an SEC filing |
| Apr 4, 2025 | Tactic Pharma LLC first listed as Chief Executive Officer in an SEC filing |
| Mar 3, 2025 | Quan Anh Vu became Chief Financial Officer |
| Feb 27, 2025 | The company announced the departure of Karthik Radhakrishnan as Chief Financial Officer in an SEC filing |
| Feb 21, 2025 | Lavina Talukdar became a director |
| Dec 17, 2024 | TacticGem LLC reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2024 | Karthik Radhakrishnan became Chief Financial Officer |
| May 23, 2024 | The company announced the departure of Kim R Tsuchimoto as Chief Financial Officer in an SEC filing |
| Apr 4, 2023 | Kim R Tsuchimoto first listed as a director in an SEC filing |
| Jul 12, 2021 | Jose Octavio Pinto Costa Filho became Chief Medical Officer |
| Jun 1, 2021 | Andrew Cittadine became Chief Operating Officer |
| Feb 20, 2020 | Michael J Brown no longer listed as a 10% owner in SEC filings |
| Feb 20, 2020 | Chandler Robinson no longer listed as a 10% owner in SEC filings |
| Feb 20, 2020 | Andrew Paul Mazar no longer listed as a 10% owner in SEC filings |
| Jan 8, 2018 | Thomas V. O'Halloran became a 10% owner |
| Jan 8, 2018 | TacticGem LLC became a 10% owner |
| Jan 8, 2018 | Tactic Pharma LLC became a 10% owner |
| Jan 8, 2018 | Raymond Anderson became a director |
| Jan 8, 2018 | Pharma Investments LLC became a 10% owner |
| Jan 8, 2018 | Michael J Brown became a director |
| Jan 8, 2018 | Michael J Brown became a 10% owner |
| Jan 8, 2018 | Kirsten Anderson became SVP, Clinical Development |
| Jan 8, 2018 | Kim R Tsuchimoto became Chief Financial Officer |
| Jan 8, 2018 | Karl Leo became a 10% owner |
| Jan 8, 2018 | Gem Pharmaceuticals LLC became a 10% owner |
| Jan 8, 2018 | Diane Hendricks became a 10% owner |
| Jan 8, 2018 | Christopher M Starr became a director |
| Jan 8, 2018 | Chandler Robinson became a director |
| Jan 8, 2018 | Chandler Robinson became a 10% owner |
| Jan 8, 2018 | Chandler Robinson became Chief Executive Officer |
| Jan 8, 2018 | Arthur J Klausner became a director |
| Jan 8, 2018 | Andrew Paul Mazar became a director |
| Jan 8, 2018 | Andrew Paul Mazar became a 10% owner |
| Jan 8, 2018 | Andrew Paul Mazar became Chief Scientific Officer |
Not reported recently (5)
- Jose Octavio Pinto Costa Filho · Last reported as Chief Medical Officer in an SEC filing dated Jul 13, 2021
- Karl Leo · Last reported as a 10% owner in an SEC filing dated Dec 20, 2019
- Gem Pharmaceuticals LLC · Last reported as a 10% owner in an SEC filing dated Jan 8, 2018
- Pharma Investments LLC · Last reported as a 10% owner in an SEC filing dated Jan 8, 2018
- Kirsten Anderson · Last reported as SVP, Clinical Development in an SEC filing dated Jan 8, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MNPR Proposed Insider Sales (Form 144)
Latest: 2026-10-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
5 filings
· $5.5M notice value
· 5 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
CHANDLER ROBINSON (1, $2.6M) · CHRISTOPHER STARR (1, $1.3M) · KIM TSUCHIMOTO (1, $907K) · RAYMOND WILLIAM ANDERSON (1, $700K) · PATRICE RIOUX (1, $111)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-01 | CHRISTOPHER STARR | Director | 16,800 | $1.34M | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-24 | CHANDLER ROBINSON | Director, Officer | 29,056 | $2.60M | 2026-09-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-26 | PATRICE RIOUX | Acting Chief Medical Officer | 1 | $111 | 2026-08-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-26 | KIM TSUCHIMOTO | Director | 8,180 | $906.5K | 2026-08-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-25 | RAYMOND WILLIAM ANDERSON | Director | 6,284 | $699.8K | 2026-08-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-10 144/A | Arthur Klausner | Former Board Member | 5,000 | $477.0K | 2026-07-08 | MLPFS | — | EDGAR |
| 2025-12-19 | Arthur Klausner | Board Member | 5,121 | $343.9K | 2025-12-18 | MLPFS | — | EDGAR |
| 2025-07-14 | STARR CHRISTOPHER M | Director | 16,800 | $672.0K | 2025-07-14 | Merrill Lynch Pierce Fenner & Sm… | — | EDGAR |
| 2025-07-14 | Tsuchimoto Kim R | Director | 8,904 | $356.2K | 2025-07-14 | Merrill Lynch Pierce Fenner & Sm… | — | EDGAR |
| 2025-07-14 | Robinson Chandler | Officer, Director | 16,800 | $672.0K | 2025-07-14 | Merrill Lynch Pierce Fenner & Sm… | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
26 ETFs hold MNPR
25 shown · $44.87M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $12.7M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.10% | $10.3M | $10.8B | 2026-10-29 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $8.2M | $75.5B | 2026-10-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.3M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.2M | $14.1B | 2026-10-30 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.1M | — | 2026-09-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.08% | $961,978 | $1.2B | 2026-10-30 |
| 8 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $744,126 | $14.0B | 2026-10-30 |
| 9 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $591,819 | $6.9B | 2026-10-29 |
| 10 | BBC Virtus Biotech Clinical Trials Etf | Nport | 1.21% | $563,420 | — | 2026-07-31 |
| 11 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.06% | $434,121 | — | 2026-10-30 |
| 12 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $366,086 | $95.5B | 2026-10-30 |
| 13 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.02% | $300,728 | — | 2026-10-29 |
| 14 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $247,853 | — | 2026-09-30 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $236,296 | $3.2B | 2026-10-29 |
| 16 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.02% | $170,283 | $1.1B | 2026-10-29 |
| 17 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $153,790 | — | 2026-10-30 |
| 18 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $131,287 | $20.2B | 2026-10-30 |
| 19 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $99,109 | — | 2026-09-30 |
| 20 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $33,461 | — | 2026-09-30 |
| 21 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $17,791 | — | 2026-10-30 |
| 22 | URTY ProShares UltraPro Russell2000 | ProShares | 0.01% | $13,853 | — | 2026-10-30 |
| 23 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $9,845 | — | 2026-10-30 |
| 24 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.01% | $463 | — | 2026-06-30 |
| 25 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $352 | — | 2026-10-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.